Four Reasons Why Amgen Won’t Break Up
October 22, 2014 at 11:59 AM EDT
Amgen (AMGN) has been a popular target for activist investors, who would like to see the biotech giant split itself in two. In a note published yesterday, RBC Capital Markets’ Michael Yee and team explain why that he doesn’t think that’s likely to happen: Reuters This is because based on long conversations with Amgen, 1) [...]
